Elutia Inc
ELUT
NASDAQ·Healthcare·Biotechnology·Mkt cap $36.3M
$0.82
▼ -2.24%
P/E
—
Mkt Cap
$36.3M
52-Wk Range
$0.50–$2.04
52-Week Range
$0.50 - $2.04
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 56.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary drug-eluting biologic technology platform
- Established relationships with hospitals and healthcare systems
- FDA-cleared products with clinical validation in high-need markets
- Differentiated anti-infective and tissue repair solutions
Bear Case
1 risk
- Average volatility.
Growth
Profitability at risk
Increasing adoption of device protection solutions in cardiac procedures
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-17.1% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ELUT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 13, 2026
Reported EPS of -$0.17 vs -$0.15 consensus (-13.3% surprise). Revenue of $2.4M vs $2.9M expected (-16.3%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-13.3%
Revenue trend · last 8Q
—
—
-10%
-0%
-44%
-40%
-48%
-61%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$5.9M
$5.5M
$6.0M
$6.3M
$3.3M
$3.3M
$3.1M
$2.4M
Margins · last 8Q
Gross
59.6%
Operating
—
Profit
-315.0%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How ELUT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related